Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
about
Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure.Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysiSESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-laPositive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.
P2860
Q30394059-7C745453-0D49-4FF5-8519-17C0975D11B3Q33712438-01182708-7610-4566-9E35-95C0AAE6BA65Q38853002-4DD7217D-A1A8-4234-988C-395BEB351790Q41926589-520744F2-C5A4-452C-9908-F75E0CC4EF26Q41929466-58550617-47FF-4F8A-91EB-123FCFA99D3DQ45323778-7406C138-1617-48CA-9AE7-C32FA767C70CQ47258937-A4F938D8-BCE8-45E1-974C-B654BE98BB58Q49344179-9E218BF5-7AA4-4766-8B32-C62524918EE6Q53694767-1346971A-F7CB-49E5-87C5-A31DA6280869
P2860
Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Protease Inhibitor Resistance ...... r HIV-1 in Sub-Saharan Africa.
@en
type
label
Protease Inhibitor Resistance ...... r HIV-1 in Sub-Saharan Africa.
@en
prefLabel
Protease Inhibitor Resistance ...... r HIV-1 in Sub-Saharan Africa.
@en
P2093
P2860
P356
P1476
Protease Inhibitor Resistance ...... or HIV-1 in Sub-Saharan Africa
@en
P2093
Alani Sulaimon Akanmu
Cissy M Kityo
Cleophas Chimbetete
Eman E F Labib Maksimos
Kim C E Sigaloff
Kishor Mandaliya
Margaret Siwale
Mariette E Botes
Maureen Wellington
Pascale Ondoa
P2860
P304
P356
10.1093/INFDIS/JIW219
P407
P577
2016-07-11T00:00:00Z